![Alex Tonks BSc (Hons), PhD, FHEA](https://profiles-cardiff.imgix.net/attachments/4119?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Alex Tonks
(e/fe)
BSc (Hons), PhD, FHEA
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Alex Tonks
Cyd-Bennaeth yr Adran Canser a Geneteg
Trosolwyg
Fel Cyd-Bennaeth yr Adran Canser a Geneteg (DCG) a Phennaeth dros dro yr Adran Haematoleg ym Mhrifysgol Caerdydd (2026), rwy'n gyrru gwaith hanfodol yn yr Ysgol Feddygaeth. Am 30 mlynedd, rydw i wedi mireinio fy ymarfer proffesiynol mewn ymchwil labordy, gan ddod ag arbenigedd dwfn mewn arweinyddiaeth, rheolaeth ac addysgu arloesol ar draws pob lefel (UG i PGR). Rwy'n hyrwyddo trylwyredd, ansawdd a chynhwysiant ym mhob lleoliad ymchwil ac addysgol.
Fy mhrif ffocws yw arwain grŵp amlddisgyblaethol sy'n mynd i'r afael â malaenedd haematolegol (canser y gwaed). Yn benodol, mae fy ymchwil yn canolbwyntio ar lewcemia myeloid acíwt (AML), gan geisio nodi biofarcwyr newydd, targedau cyffuriau, a thriniaethau mwy newydd. Rwy'n ymchwilio i sut mae genynnau a llwybrau ymgeiswyr - megis proteinau metabolig / S100, signalau, rheoleiddwyr imiwnedd yn dysreoleiddio datblygiad celloedd gwaed neu ganiatáu i gelloedd canser y gwaed oroesi.
Y tu hwnt i'r labordy, rwy'n defnyddio fy arbenigedd i ddylanwadu ar gyllid, strategaeth a chefnogi datblygiad gwyddonwyr ymchwil ar ddechrau a chanol gyrfa. Rwy'n arwain ac yn cadeirio paneli cyllido elusennau cenedlaethol y DU ac yn gwasanaethu fel cynghorydd allanol i sawl elusen lewcemia. Mae fy rolau cynghori yn ymestyn i UKRI, y llywodraeth, a phwyllgorau cyllido rhyngwladol, gan helpu i ddyrannu grantiau mawr a llunio dyfodol ymchwil.
Cyhoeddiad
2026
- Ullah, S. et al., 2026. Integrated expression profiling of BCR-ABL and computational identification of ABL1 inhibitors in pediatric acute lymphoblastic leukemia. In Silico Pharmacology 14 (3) 229. (10.1007/s40203-026-00731-3)
- Azevedo, A. et al. 2026. Expression of RUNX1::RUNX1T1 deregulates the proteome, induces C/EBPβ suppression and blocks myeloid differentiation. Blood Neoplasia 3 (3) 100259. (10.1016/j.bneo.2026.100259)
2025
- Abdelfattah, A. et al. 2025. Impaired DNA damage responses and inflammatory signaling underpin hematopoietic stem cell defects in Gata2 haploinsufficiency. Stem Cell Reports 20 (8) 102596. (10.1016/j.stemcr.2025.102596)
2024
- Rizzo, S. et al. 2024. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia. International Journal of Nanomedicine 19 , pp.5419-5437. (10.2147/IJN.S449185)
- Sorouri Khorashad, J. , Rizzo, S. and Tonks, A. 2024. Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia. Cancer Drug Resistance 7 5. (10.20517/cdr.2023.125)
2023
- Ullah, S. et al. 2023. Whole exome sequence of Pakistani acute lymphocytic leukemia patient from Pakhtuns ancestry reveal the novel genetic variant characterization in the GLDC gene. Journal of Biotechnology and Biomedicine 06 (03), pp.409-420. (10.26502/jbb.2642-91280103)
- Rastogi, N. et al. 2023. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia. Leukemia 37 , pp.276-287. (10.1038/s41375-022-01801-z)
- Wagstaff, M. et al., 2023. Crosstalk between β-catenin and WT1 signalling activity in acute myeloid leukemia [Letters to the Editor]. Haematologica 108 (1)(10.3324/haematol.2021.280294)
2022
- Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132 (21) e150750. (10.1172/JCI150750)
- Menezes, A. C. et al. 2022. Increased expression of RUNX3 inhibits normal human myeloid development. Leukemia 36 , pp.1769-1780. (10.1038/s41375-022-01577-2)
- Ullah, S. et al., 2022. A Case report of rare disease Prolidase deficiency in a 15-year-old Pakistan boy. Journal of Rare Diseases Research & Treatment 7 (2), pp.1-4. (10.29245/2572-9411/2022/2.1206)
- Nicholson, R. et al. 2022. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. Frontiers in Oncology 12 840046. (10.3389/fonc.2022.840046)
- Hillier, J. et al., 2022. The BCAT1 CXXC motif provides protection against ROS in acute myeloid leukaemia cells. Antioxidants 11 (4) 683. (10.3390/antiox11040683)
- Menezes, A. C. et al. 2022. RUNX3 overexpression inhibits normal human erythroid development. Scientific Reports 12 1243. (10.1038/s41598-022-05371-z)
2021
- Abdelfattah, A. M. et al., 2021. Gata2 haploinsufficiency promotes proliferation and functional decline of HSCs with myeloid bias during aging. Blood Advances 5 (20), pp.4285-4290. (10.1182/bloodadvances.2021004726)
- Robinson, A. J. , Darley, R. L. and Tonks, A. 2021. Reactive oxygen species in leukemias: maintaining cancer cell proliferation via redox signaling and changing metabolic homeostasis. Oncotarget 12 (10), pp.952-954. (10.18632/oncotarget.27913)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1), pp.155-159. (10.1111/bjh.17125)
- Robinson, A. J. , Darley, R. L. and Tonks, A. 2021. Reactive oxygen species and metabolic re-wiring in acute leukemias. In: Piccaluga, P. P. ed. Acute Leukemias. IntechOpen. , pp.35-56. (10.5772/intechopen.94829)
- Robinson, A. J. et al., 2021. Reactive oxygen species rewires metabolic activity in acute myeloid leukemia. Frontiers in Oncology 11 632623. (10.3389/fonc.2021.632623)
- Tonks, A. 2021. Make your cake and eat it: refueling of immune fitness in AML post allo-HCT using baking soda. Immunometabolism 3 (1) e210005. (10.20900/immunometab20210005)
2020
- Abate, W. et al., 2020. Lysophosphatidylcholine acyltransferase 2 (LPCAT2) co-localises with TLR4 and regulates macrophage inflammatory gene expression in response to LPS. Scientific Reports 10 (1) 10355. (10.1038/s41598-020-67000-x)
- Robinson, A. J. et al. 2020. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Cancer Research 80 (5), pp.937-949. (10.1158/0008-5472.CAN-19-1920)
- Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34 (2), pp.427-440. (10.1038/s41375-019-0596-4)
2019
- Menendez Gonzalez, J. B. et al. 2019. Gata2 as a crucial regulator of stem cells in adult hematopoiesis and acute myeloid leukemia. Stem Cell Reports 13 (2), pp.291-306. (10.1016/j.stemcr.2019.07.005)
- Morgan, R. G. et al., 2019. LEF-1 drives aberrant B-catenin nuclear localization in myeloid leukemia cells. Haematologica 104 , pp.1365-1377. 202846. (10.3324/haematol.2018.202846)
2018
- Hassan, N. et al., 2018. TET-2 up-regulation is associated with the anti-inflammatory action of Vicenin-2. Cytokine 108 , pp.37-42. (10.1016/j.cyto.2018.03.016)
2015
- Munje, C. et al. 2015. Cord blood-derived quiescent CD34+ cells are more transcriptionally matched to AML blasts than cytokine-induced normal human hematopoietic CD34+ cells. Gene Expression: International Journal of Molecular and Cellular Science 16 (4), pp.169-175. (10.3727/105221615X14399878166159)
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp.1952-1954. (10.1038/leu.2015.62)
2014
- Morgan, R. G. et al., 2014. Factors affecting the nuclear localization of β-Catenin in normal and malignant tissue. Journal of Cellular Biochemistry 115 (8), pp.1351-1361. (10.1002/jcb.24803)
- Zabkiewicz, J. et al. 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99 (5), pp.858-864. (10.3324/haematol.2013.096487)
2013
- Hole, P. S. et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122 (19), pp.3322-3330. (10.1182/blood-2013-04-491944)
- Morgan, R. G. et al. 2013. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia 27 (2), pp.336-343. (10.1038/leu.2012.221)
2012
- Daud, S. S. et al. 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120 (21) 1281.
- Coles, S. et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9), pp.2148-2151. (10.1038/leu.2012.77)
- Coles, S. et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9), pp.2146-2148. (10.1038/leu.2012.75)
- Liddiard, K. et al. 2012. RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1 [Letter]. Leukemia 26 (1), pp.177-179. (10.1038/leu.2011.188)
2011
- Coles, S. et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5), pp.792-799. (10.1038/leu.2011.1)
- Coles, S. et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1), pp.178. (10.1111/j.1365-2567.2011.03534.x)
- Hole, P. S. , Darley, R. L. and Tonks, A. 2011. Do reactive oxygen species play a role in myeloid leukemias?. Blood 117 (22), pp.5816-5826. (10.1182/blood-2011-01-326025)
2010
- Zabkiewicz, J. et al. 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116 (21), pp.892-893.
- Morgan, R. G. et al. 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116 (21) 1573.
- Hole, P. S. et al. 2010. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood 115 (6), pp.1238-1246. (10.1182/blood-2009-06-222869)
- Coles, S. et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21), pp.218-218.
- Liddiard, K. et al. 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29 (13), pp.2005-2012. (10.1038/onc.2009.462)
2008
- Morris, R. H. K. et al., 2008. DPPC regulates COX-2 expression in monocytes via phosphorylation of CREB. Biochemical and Biophysical Research Communications 370 (1), pp.174-178. (10.1016/j.bbrc.2008.03.052)
2007
- Tonks, A. et al. 2007. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 21 (12), pp.2495-2505. (10.1038/sj.leu.2404961)
- Walsby, E. J. et al. 2007. FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology 139 (1), pp.94-97. (10.1111/j.1365-2141.2007.06756.x)
- Tonks, A. J. et al. 2007. A 5.8KDa component of manuka honey stimulates immune cells via TLR4. Journal of Leukocyte Biology 82 (5), pp.1147-1155. (10.1189/jlb.1106683)
- Tonks, A. et al. 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21 (3), pp.566-568. (10.1038/sj.leu.2404559)
- Tonks, A. et al. 2007. CD200 as a prognostic factor in acute myeloid leukaemia [Letter]. Leukemia 21 (3), pp.566-568. (10.1038/sj.leu.2404559)
2006
- Tonks, A. et al. 2006. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia 20 (10), pp.1883-5. (10.1038/sj.leu.2404364)
2005
- Tonks, A. et al. 2005. Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC. AJP Lung Cellular and Molecular Physiology 288 (6), pp.1070-80. (10.1152/ajplung.00386.2004)
- Tonks, A. et al. 2005. Optimized retroviral transduction protocol which preserves the primitive subpopulation of human hematopoietic cells. Biotechnology Progress 21 (3), pp.953-958. (10.1021/bp0500314)
2004
- Tonks, A. et al. 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18 (7), pp.1238-1245. (10.1038/sj.leu.2403396)
2003
- Tonks, A. et al. 2003. The AML-1 ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101 (2), pp.624-632. (10.1182/blood-2002-06-1732)
- Tonks, A. J. et al. 2003. Regulation of platelet-activating factor synthesis in human monocytes by dipalmitoyl phosphatidylcholine. Journal of Leukocyte Biology 74 (1), pp.95-101. (10.1189/jlb.1202601)
Adrannau llyfrau
- Robinson, A. J. , Darley, R. L. and Tonks, A. 2021. Reactive oxygen species and metabolic re-wiring in acute leukemias. In: Piccaluga, P. P. ed. Acute Leukemias. IntechOpen. , pp.35-56. (10.5772/intechopen.94829)
Erthyglau
- Ullah, S. et al., 2026. Integrated expression profiling of BCR-ABL and computational identification of ABL1 inhibitors in pediatric acute lymphoblastic leukemia. In Silico Pharmacology 14 (3) 229. (10.1007/s40203-026-00731-3)
- Azevedo, A. et al. 2026. Expression of RUNX1::RUNX1T1 deregulates the proteome, induces C/EBPβ suppression and blocks myeloid differentiation. Blood Neoplasia 3 (3) 100259. (10.1016/j.bneo.2026.100259)
- Abdelfattah, A. et al. 2025. Impaired DNA damage responses and inflammatory signaling underpin hematopoietic stem cell defects in Gata2 haploinsufficiency. Stem Cell Reports 20 (8) 102596. (10.1016/j.stemcr.2025.102596)
- Rizzo, S. et al. 2024. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia. International Journal of Nanomedicine 19 , pp.5419-5437. (10.2147/IJN.S449185)
- Sorouri Khorashad, J. , Rizzo, S. and Tonks, A. 2024. Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia. Cancer Drug Resistance 7 5. (10.20517/cdr.2023.125)
- Ullah, S. et al. 2023. Whole exome sequence of Pakistani acute lymphocytic leukemia patient from Pakhtuns ancestry reveal the novel genetic variant characterization in the GLDC gene. Journal of Biotechnology and Biomedicine 06 (03), pp.409-420. (10.26502/jbb.2642-91280103)
- Rastogi, N. et al. 2023. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia. Leukemia 37 , pp.276-287. (10.1038/s41375-022-01801-z)
- Wagstaff, M. et al., 2023. Crosstalk between β-catenin and WT1 signalling activity in acute myeloid leukemia [Letters to the Editor]. Haematologica 108 (1)(10.3324/haematol.2021.280294)
- Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132 (21) e150750. (10.1172/JCI150750)
- Menezes, A. C. et al. 2022. Increased expression of RUNX3 inhibits normal human myeloid development. Leukemia 36 , pp.1769-1780. (10.1038/s41375-022-01577-2)
- Ullah, S. et al., 2022. A Case report of rare disease Prolidase deficiency in a 15-year-old Pakistan boy. Journal of Rare Diseases Research & Treatment 7 (2), pp.1-4. (10.29245/2572-9411/2022/2.1206)
- Nicholson, R. et al. 2022. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. Frontiers in Oncology 12 840046. (10.3389/fonc.2022.840046)
- Hillier, J. et al., 2022. The BCAT1 CXXC motif provides protection against ROS in acute myeloid leukaemia cells. Antioxidants 11 (4) 683. (10.3390/antiox11040683)
- Menezes, A. C. et al. 2022. RUNX3 overexpression inhibits normal human erythroid development. Scientific Reports 12 1243. (10.1038/s41598-022-05371-z)
- Abdelfattah, A. M. et al., 2021. Gata2 haploinsufficiency promotes proliferation and functional decline of HSCs with myeloid bias during aging. Blood Advances 5 (20), pp.4285-4290. (10.1182/bloodadvances.2021004726)
- Robinson, A. J. , Darley, R. L. and Tonks, A. 2021. Reactive oxygen species in leukemias: maintaining cancer cell proliferation via redox signaling and changing metabolic homeostasis. Oncotarget 12 (10), pp.952-954. (10.18632/oncotarget.27913)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1), pp.155-159. (10.1111/bjh.17125)
- Robinson, A. J. et al., 2021. Reactive oxygen species rewires metabolic activity in acute myeloid leukemia. Frontiers in Oncology 11 632623. (10.3389/fonc.2021.632623)
- Tonks, A. 2021. Make your cake and eat it: refueling of immune fitness in AML post allo-HCT using baking soda. Immunometabolism 3 (1) e210005. (10.20900/immunometab20210005)
- Abate, W. et al., 2020. Lysophosphatidylcholine acyltransferase 2 (LPCAT2) co-localises with TLR4 and regulates macrophage inflammatory gene expression in response to LPS. Scientific Reports 10 (1) 10355. (10.1038/s41598-020-67000-x)
- Robinson, A. J. et al. 2020. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Cancer Research 80 (5), pp.937-949. (10.1158/0008-5472.CAN-19-1920)
- Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34 (2), pp.427-440. (10.1038/s41375-019-0596-4)
- Menendez Gonzalez, J. B. et al. 2019. Gata2 as a crucial regulator of stem cells in adult hematopoiesis and acute myeloid leukemia. Stem Cell Reports 13 (2), pp.291-306. (10.1016/j.stemcr.2019.07.005)
- Morgan, R. G. et al., 2019. LEF-1 drives aberrant B-catenin nuclear localization in myeloid leukemia cells. Haematologica 104 , pp.1365-1377. 202846. (10.3324/haematol.2018.202846)
- Hassan, N. et al., 2018. TET-2 up-regulation is associated with the anti-inflammatory action of Vicenin-2. Cytokine 108 , pp.37-42. (10.1016/j.cyto.2018.03.016)
- Munje, C. et al. 2015. Cord blood-derived quiescent CD34+ cells are more transcriptionally matched to AML blasts than cytokine-induced normal human hematopoietic CD34+ cells. Gene Expression: International Journal of Molecular and Cellular Science 16 (4), pp.169-175. (10.3727/105221615X14399878166159)
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp.1952-1954. (10.1038/leu.2015.62)
- Morgan, R. G. et al., 2014. Factors affecting the nuclear localization of β-Catenin in normal and malignant tissue. Journal of Cellular Biochemistry 115 (8), pp.1351-1361. (10.1002/jcb.24803)
- Zabkiewicz, J. et al. 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99 (5), pp.858-864. (10.3324/haematol.2013.096487)
- Hole, P. S. et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122 (19), pp.3322-3330. (10.1182/blood-2013-04-491944)
- Morgan, R. G. et al. 2013. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia 27 (2), pp.336-343. (10.1038/leu.2012.221)
- Daud, S. S. et al. 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120 (21) 1281.
- Coles, S. et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9), pp.2148-2151. (10.1038/leu.2012.77)
- Coles, S. et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9), pp.2146-2148. (10.1038/leu.2012.75)
- Liddiard, K. et al. 2012. RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1 [Letter]. Leukemia 26 (1), pp.177-179. (10.1038/leu.2011.188)
- Coles, S. et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5), pp.792-799. (10.1038/leu.2011.1)
- Coles, S. et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1), pp.178. (10.1111/j.1365-2567.2011.03534.x)
- Hole, P. S. , Darley, R. L. and Tonks, A. 2011. Do reactive oxygen species play a role in myeloid leukemias?. Blood 117 (22), pp.5816-5826. (10.1182/blood-2011-01-326025)
- Zabkiewicz, J. et al. 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116 (21), pp.892-893.
- Morgan, R. G. et al. 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116 (21) 1573.
- Hole, P. S. et al. 2010. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood 115 (6), pp.1238-1246. (10.1182/blood-2009-06-222869)
- Coles, S. et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21), pp.218-218.
- Liddiard, K. et al. 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29 (13), pp.2005-2012. (10.1038/onc.2009.462)
- Morris, R. H. K. et al., 2008. DPPC regulates COX-2 expression in monocytes via phosphorylation of CREB. Biochemical and Biophysical Research Communications 370 (1), pp.174-178. (10.1016/j.bbrc.2008.03.052)
- Tonks, A. et al. 2007. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 21 (12), pp.2495-2505. (10.1038/sj.leu.2404961)
- Walsby, E. J. et al. 2007. FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology 139 (1), pp.94-97. (10.1111/j.1365-2141.2007.06756.x)
- Tonks, A. J. et al. 2007. A 5.8KDa component of manuka honey stimulates immune cells via TLR4. Journal of Leukocyte Biology 82 (5), pp.1147-1155. (10.1189/jlb.1106683)
- Tonks, A. et al. 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21 (3), pp.566-568. (10.1038/sj.leu.2404559)
- Tonks, A. et al. 2007. CD200 as a prognostic factor in acute myeloid leukaemia [Letter]. Leukemia 21 (3), pp.566-568. (10.1038/sj.leu.2404559)
- Tonks, A. et al. 2006. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia 20 (10), pp.1883-5. (10.1038/sj.leu.2404364)
- Tonks, A. et al. 2005. Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC. AJP Lung Cellular and Molecular Physiology 288 (6), pp.1070-80. (10.1152/ajplung.00386.2004)
- Tonks, A. et al. 2005. Optimized retroviral transduction protocol which preserves the primitive subpopulation of human hematopoietic cells. Biotechnology Progress 21 (3), pp.953-958. (10.1021/bp0500314)
- Tonks, A. et al. 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18 (7), pp.1238-1245. (10.1038/sj.leu.2403396)
- Tonks, A. et al. 2003. The AML-1 ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101 (2), pp.624-632. (10.1182/blood-2002-06-1732)
- Tonks, A. J. et al. 2003. Regulation of platelet-activating factor synthesis in human monocytes by dipalmitoyl phosphatidylcholine. Journal of Leukocyte Biology 74 (1), pp.95-101. (10.1189/jlb.1202601)
Ymchwil
Trosolwg o Ymchwil
Mae lewcemia myeloid acíwt (AML) yn dal i gael canlyniad gwael yn gyffredinol, yn enwedig i'r rhai dros drigain oed. Daw gobaith ar gyfer y dyfodol ar ffurf triniaethau sy'n targedu annormaleddau allweddol sy'n "sawdl Achilles" y clefyd; Yn anffodus, mae AML yn glefyd amrywiol iawn a dim ond un is-deip o'r clefyd sy'n cael ei drin yn y modd hwn ar hyn o bryd. Rwy'n ymchwilio i rolau nifer o enynnau ymgeisiol gan gynnwys RUNX1::ETO, RUNX3, hnRNP, CD200, signalau Wnt, S100 a chynhyrchu rhywogaethau ocsigen adweithiol (ROS) mewn leukaemogenesis. Yn benodol, mae gen i ddiddordeb mewn sut mae'r broses o ddatblygiad haematopoietig mewn poblogaethau coesyn a rhagflaenwyr yn cael ei gamreoleiddio gan y genynnau hyn mewn AML.
Disgrifiad Ymchwil
Mae trawsleoliadau sy'n effeithio ar y ffactor trawsgrifio RUNX1 ymhlith y rhai mwyaf cyffredin mewn AML a preleucemia. Mae modelau knockout wedi dangos pwysigrwydd y genyn hwn ar gyfer datblygiad haematopoietig, fodd bynnag, ar hyn o bryd rydym yn deall ychydig o effaith genynnau RUNX1 wedi'u trawsleoli fel RUNX1::ETO ar ddatblygiad celloedd dynol cynradd. Nod ein hastudiaethau oedd cael dealltwriaeth fanwl o effaith RUNX1::ETO ar ddatblygiad celloedd cynradd dynol cyntefig. Rydym wedi cyflawni hyn trwy fynegi RUNX1::ETO yn ectopig yn CD34+ gan ddefnyddio fector retroviral sy'n cyd-fynegi protein fflwroleuol gwyrdd. Roedd hyn yn galluogi adnabod celloedd heintiedig mewn 'amser real', ac yn caniatáu inni astudio effeithiau RUNX1::ETO ar gelloedd cyntefig ac ar eu gallu dilynol i gwblhau eu gwahaniaethu i lawr y llinellau myeloid ac erythroid. Gan ddefnyddio'r dull hwn, dangoswyd bod mynegiant RUNX1::ETO yn atal gwahaniaethu celloedd myeloid ac erythroid yn gryf yn ogystal â hyrwyddo eu hunan-adnewyddu. Wedi hynny, rydym wedi defnyddio technoleg microarray i nodi genynnau targed RUNX1::ETO. Ar hyn o bryd rydym yn ymchwilio i'r genynnau hyn a'u gallu i ailadrodd ffenoteip RUNX1::ETO.
Rydym hefyd wedi nodi annormaledd sy'n gyffredin i'r mwyafrif o gleifion AML, sef gorgynhyrchu rhywogaethau ocsigen adweithiol (ROS). Er bod ROS yn niweidiol i gelloedd gwaed arferol, mae celloedd AML wedi datblygu ymwrthedd iddynt ac ar ben hynny yn dibynnu ar ROS i hyrwyddo eu twf. Ar hyn o bryd rydym yn ymchwilio i ddulliau a all fod yn effeithiol yn erbyn celloedd AML trwy ddefnyddio asiantau sy'n llawer haws eu goddef na chemotherapi confensiynol.
Mae gwybod pa enynnau, proteinau (a ROS) sy'n gysylltiedig â chynhyrchu gwaed annormal yn ein galluogi i ddatblygu triniaethau newydd sydd eu hangen yn hanfodol ar gyfer cleifion ag AML.
Grantiau a gynhaliwyd yn ystod y 5 mlynedd diwethaf
1. CCRH. Ysgoloriaeth PhD. Rôl genynnau ymasiad NFIA mewn lewcemia erythroid. Yr Athro Tonks (PI), R Darley (Cyd-ap), Yr Athro Knapper (Cyd-ap). 2024-2027: £103,487.
2. LMUK. Grant prosiect bach. Deall rheoleiddio cyfryngol ZEB1 mewn AML dynol. Dr Rodrigues (PI), Yr Athro Tonks (Cyd-ap). 2024-2025: £35,000.
3. BloodCancer UK. Prosiect Peilot. Nodweddu'r is-clonau AML sydd â'r potensial i oroesi'r cemotherapi safonol ar y diagnosis. Yr Athro Tonks (PI), Dr Khorashad (Cyd-PI), Yr Athro Darley (Cyd-ap). 2024-2025: £30,000.
4. BloodCancer UK. Grant prosiect. Rheoleiddio cyfryngu Zeb1 o gelloedd cychwyn / bôn-gelloedd lewcemig llygoden a dynol (LICs) mewn lewcemia myeloid acíwt. Dr Rodrigues (PI), Yr Athro Tonks (Cyd-App). 2024-2027: £250,000.
5. Ymchwil Gofal Iechyd Cymru. Ysgoloriaeth PhD sy'n pennu rôl NFIC mewn AML. Yr Athro Tonks (PI): Dr H WIlliams (Cyd-ap), Yr Athro Darley (Cyd-ap). 2022-2025; £66,000.
6. Canser y Gwaed yn y DU. Grant prosiect sy'n archwilio NOX2 fel elfen o therapi aml-darged ar gyfer myeloid acíwt. Yr Athro Tonks (PI): Dr Khorashad (Co-I), Yr Athro Darley (Cyd-ap). 2022-2025; £248,000.
7. Ysgoloriaeth PhD Cenhadaeth Ddiwylliannol Saudi Arabia. Rôl proteinau hnRNP mewn leukaemogenesis. Ysgoloriaeth PhD. Yr Athro Tonks (PI), Yr Athro Darley (Cyd-ap). 2021-2025: £146,000.
8. Ysgoloriaeth PhD Cenhadaeth Ddiwylliannol Saudi Arabia. Adnabod a dilysu targedau therapiwtig newydd a biofarcwyr mewn lewcemia myeloid acíwt. Yr Athro Darley (PI), Yr Athro Tonks (Cyd-ap). 2021-2025: £142,000.
9. Wellcome ISSF Gwobr cychwyn cychwyn trosiannol. Cyfieithiad PFKFB3 mewn AML. A Tonks (PI), R Darley, S Knaper (Cyd-ap). 2020-2021. £37,645.
10. Wellcome ISSF Gwobr cychwyn cychwyn trosiannol. Sgrinio gweithgaredd gwrthganser therapiwteg polymer gwrthfiotig newydd. (Elain Ferguson PI, A Tonks, Co-app ac Arwyn Jones Co-app). 2019-2020. £49,645.
11. Ysgoloriaeth PhD. Rôl signalau Wnt yn natblygiad bôn-gelloedd gwaed ac mewn lewcemia myeloid acíwt Yr Athro Darley (PI), Dr Tonks (Co-app). 2018-2021: £75,000.
Addysgu
- Rwy'n Gymrawd o'r Higher Education Acadamy.
- Rwy'n cyfrannu at addysgu sy'n gysylltiedig â sawl cwrs a modiwl ar draws yr Ysgol a'r Colegau ym Mhrifysgol Caerdydd.
- Rwy'n darparu sawl prosiect labordy ar gyfer myfyrwyr israddedig, ôl-raddedig, MRes a PTY i hyfforddi yn fy labordy.
- Rwy'n ddarlithydd allanol ar gyfer sawl prifysgol yn y DU ac yn siaradwr gwadd yn rhyngwladol.
- Rwy'n arholwr allanol i fyfyrwyr PGR.
- Rwy'n arholwr allanol ar gyfer cyrsiau BSc/MSi.
Bywgraffiad
Education and significant professional training courses
2014: Fellow of the Higher Education Academy
2012-2014: ILM endorsed course for Practical Leadership for University Management, Cardiff University, Cardiff, UK
2012-2013: CPD in Medical Education Orientation Programme, School of Medicine, Cardiff University, Cardiff UK
1997-2000: PhD – Pulmonary immunology/ROS, Cardiff University / University of Wales Institute Cardiff (UWIC)
1996: HPC Registration for Biomedical Sciences, Health Professions Council, UK
1993-1997: BSc (Hons) Biomedical Sciences (Ist Class), UWIC, Cardiff, UK
Career Overview
**Present - Senior Lecturer, Department of Haematology, Cardiff University, UK
2003-2009 - Lecturer, Department of Haematology, Cardiff University, UK
2000-2003 - Post-doctoral Research Fellow, Department of Haematology, Cardiff University, UK
2000-2002 - Part time Lecturer, School of Applied Sciences, UWIC, Cardiff, UK
1997-2000 - Research Assistant, School of Applied Sciences, UWIC, Cardiff, UK
1995-1996, 1997 - Biomedical Scientist, Royal Gwent Hospital, Pathology Department, Newport, UK
Aelodaethau proffesiynol
- Rwy'n Gymrawd yr Academi Addysg Uwch (2014).
Safleoedd academaidd blaenorol
Trosolwg o Yrfa
2026 - Presennol - Cyd-Bennaeth yr Adran Canser a Geneteg, Prifysgol Caerdydd, DU
2020 - Presennol - Athro mewn Haematoleg, Adran Haematoleg, Prifysgol Caerdydd, DU
2025-2026 - Cyd-gyfarwyddwr yr Is-adran Canser a Geneteg, Prifysgol Caerdydd, DU
2024-2026 - Pennaeth Dros Dro Adran Haematoleg, Prifysgol Caerdydd, DU
2016-2020 - Darllenydd, Adran Haematoleg, Prifysgol Caerdydd , DU
2009-2016 - Uwch Ddarlithydd, Adran Haematoleg, Prifysgol Caerdydd, DU
2003-2009 - Darlithydd, Adran Haematoleg, Prifysgol Caerdydd, DU
2000-2003 - Cymrawd Ymchwil Ôl-ddoethurol, Adran Haematoleg, Prifysgol Caerdydd, DU
2000-2002 - Darlithydd Rhan Amser , Ysgol y Gwyddorau Cymhwysol, UWIC, Caerdydd, DU
1997-2000 - Cynorthwy-ydd Ymchwil , Ysgol y Gwyddorau Cymhwysol, UWIC, Caerdydd, DU
1995-1996, 1997 - Gwyddonydd Biofeddygol, Ysbyty Brenhinol Gwent, Adran Patholeg, Casnewydd, DU
Pwyllgorau ac adolygu
| Grantiau | Cyflwr |
| BBSRC (Panel C a D) | Aelod o'r Panel (wedi ymddeol) ac Adolygydd |
| Blood Cancer UK (Cymrodoriaethau) | Aelod o'r Panel ac Adolygydd |
| Lewcemia y DU | Cadeirydd, Aelod o'r Panel ac Adolygydd |
| Lewcemia a Myeloma y DU | Cyd-gadeirydd, Aelod o'r Panel |
| HCRW (Prosiectau) | Aelod o'r Panel (wedi ymddeol) |
| MRC (Cymrodorion) | Adolygydd |
| Ymchwil Canser y Gogledd Orllewin | Adolygydd |
| HCRW (Panel Cymrodoriaeth) | Aelod o'r Panel (wedi ymddeol) |
| Cymdeithas Frenhinol | Adolygydd |
| Elusen Barts | Adolygydd |
| Prifysgol Sharjah, Emiradau Arabaidd Unedig | Adolygydd |
| Sganio plant | Adolygydd |
| MRC (MCMB) | Adolygydd |
| Swyddi | Adolygydd |
| Plant â Lewcemia | Adolygydd |
| Plant C a LG | Adolygydd |
| FWF | Adolygydd |
| Cronfa Wyddoniaeth y Swistir | Adolygydd |
| Ymddiriedolaeth Wellcome | Adolygydd |
| Kay Kendall | Adolygydd |
| LLNI | Adolygydd |
| Coed Rhosyn | Adolygydd |
| ERC | Adolygydd |
| JGW Patterson | Adolygydd |
| NCR3paper size | Adolygydd |
| Cyngor RG HK | Adolygydd |
| CYMRAEG | Adolygydd |
| Swyddi | Adolygydd |
| Cymdeithas Ddynol | Adolygydd |
| David John George | Cadeirydd, Aelod o'r Panel ac Adolygydd |
| Ymddiriedolaeth Ymchwil Gogledd Cymru | Adolygydd |
Meysydd goruchwyliaeth
Mae gen i hanes ymchwil sy'n canolbwyntio ar ddeall sut mae annormaleddau moleciwlaidd sy'n gysylltiedig â lewcemia yn cyfrannu at pathogenesis y cyflyrau hyn. Rwy'n fentor profiadol gyda record goruchwylio PGR lwyddiannus rhagorol gan gynnwys datblygu ECR. Rwyf wedi goruchwylio dros 20 o fyfyrwyr PGR i'w cwblhau'n llwyddiannus. Ar hyn o bryd rwy'n goruchwylio 7 myfyriwr PhD.
Yn flaenorol, roeddwn yn Gyfarwyddwr / arweinydd PGR Rhanbarthol (~10y) sy'n gyfrifol am fonitro cynnydd ac amgylchedd PGR ~ 45 o fyfyrwyr ar draws pob blwyddyn o astudio o fewn fy Divsion. Dros yr 20 mlynedd diwethaf rwyf wedi goruchwylio nifer o fyfyrwyr BSc meddygol SSC/ffarmacolegol, graddau rhyngweithiol BSc Meddygol a myfyrwyr MPhil/MSc/MRes. Rwyf wedi bod yn arholwr mewnol / allanol neu'n gadeirydd arholiadau viva voce ar sawl achlysur. Mae fy enw da rhyngwladol yn y maes hwn yn cael ei dystiolaeth gan archwiliadau allanol yn y DU, Ewrop ac Awstralia.
Mae gen i ddiddordeb mewn goruchwylio myfyrwyr PGR ym meysydd
- Malaenedd haematolegol
- Therapïau wedi'u targedu a meddygaeth fanwl mewn canser y gwaed
- Straen ocsideiddiol a signalau REDOX mewn canser
Goruchwyliaeth gyfredol
Owen Hughes
Abdulrahman Almutairi
Sumiah Muhammed A Alghamdi
Pietro Vassallo
Contact Details
+44 29207 42235
Prif Adeilad yr Ysbyty, Llawr 7, Ystafell 187, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Themâu ymchwil
Arbenigeddau
- cancr
- Tiwmorau haematolegol
- lewcemia myeloid acíwt (AML)